IL216609A0 - Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives - Google Patents

Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives

Info

Publication number
IL216609A0
IL216609A0 IL216609A IL21660911A IL216609A0 IL 216609 A0 IL216609 A0 IL 216609A0 IL 216609 A IL216609 A IL 216609A IL 21660911 A IL21660911 A IL 21660911A IL 216609 A0 IL216609 A0 IL 216609A0
Authority
IL
Israel
Prior art keywords
triazolo
preparation
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
IL216609A
Other languages
English (en)
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL216609(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of IL216609A0 publication Critical patent/IL216609A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IL216609A 2009-06-05 2011-11-24 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives IL216609A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18453309P 2009-06-05 2009-06-05
PCT/US2010/037363 WO2010141796A2 (fr) 2009-06-05 2010-06-04 Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine

Publications (1)

Publication Number Publication Date
IL216609A0 true IL216609A0 (en) 2012-02-29

Family

ID=42985748

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216609A IL216609A0 (en) 2009-06-05 2011-11-24 Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives

Country Status (14)

Country Link
US (2) US8501936B2 (fr)
EP (1) EP2438066A2 (fr)
JP (1) JP5684245B2 (fr)
KR (1) KR20120044966A (fr)
CN (1) CN102459258B (fr)
AU (1) AU2010254806C1 (fr)
BR (1) BRPI1009637A2 (fr)
CA (1) CA2763900A1 (fr)
CL (1) CL2011003082A1 (fr)
IL (1) IL216609A0 (fr)
MX (1) MX2011012961A (fr)
NZ (1) NZ597140A (fr)
TW (1) TWI500614B (fr)
WO (1) WO2010141796A2 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155565A1 (fr) * 2008-06-20 2009-12-23 Genentech, Inc. Composés triazolopyridine inhibiteurs de jak kinase et procédés
CN102131389A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EA201300282A1 (ru) * 2010-08-27 2013-08-30 Мерк Патент Гмбх Производные триазолопиразина
CA2818936A1 (fr) 2010-12-06 2012-06-14 Cephalon, Inc. Traitement d'inflammation chronique avec un derive de 1,2,4-triazolo[1,5a]pyridine
EP2648728B1 (fr) * 2010-12-06 2016-04-27 Cephalon, Inc. Inhibiteur de la janus kinase 2 (jak2) pour le traitement du lupus
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
TWI577693B (zh) * 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
CN104114557B (zh) * 2012-02-21 2017-10-24 默克专利股份公司 作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
US20150051202A1 (en) * 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
US9284311B2 (en) * 2012-06-22 2016-03-15 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
SG11201408419QA (en) * 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
SG11201500261VA (en) * 2012-07-27 2015-02-27 Novartis Ag Prediction of treatment response to jak/stat inhibitor
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
PE20161323A1 (es) * 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法
KR102598246B1 (ko) * 2016-07-26 2023-11-02 톈진 롱보진 파마시우티컬 씨오., 엘티디. Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN109890817B (zh) * 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
EA039352B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение
WO2018167283A1 (fr) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique
EP3610264A1 (fr) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement d'un adénocarcinome canalaire pancréatique
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
JP2022509019A (ja) 2018-11-05 2022-01-20 シンジェンタ パーティシペーションズ アーゲー 殺有害生物的に活性なアゾール－アミド化合物
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
EP3877371A4 (fr) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. Dérivés d'imidazopyridine et dérivés d'aza-imidazopyridine utilisés comme inhibiteurs de la janus kinase 2 et utilisations associées
EP3876939A4 (fr) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
CA3137152A1 (fr) 2019-04-18 2020-10-22 The Johns Hopkins University Derives de 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine substitues et leur utilisation
CN111057059B (zh) * 2019-11-25 2022-04-26 广东省测试分析研究所（中国广州分析测试中心） 一种苯并二四氢吡咯类化合物或其药学上可接受的盐、及其制备方法和应用
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
AU2021362678A1 (en) 2020-10-13 2023-05-04 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023009708A1 (fr) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Hétéroaryloxy triazolo-azines et imidazo-azines en tant qu'inhibiteurs de jak2
WO2023086319A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
WO2025073290A1 (fr) * 2023-10-06 2025-04-10 Para Therapeutics, Inc. Inhibiteurs de vps4 et leurs méthodes d'utilisation
WO2025240333A1 (fr) * 2024-05-13 2025-11-20 The Texas A&M University System Médicaments intelligents ciblant la jak3 et leurs utilisations

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492696A (en) * 1989-04-14 1996-02-20 The Government Of The United States Of America As Represented By The Secretary Of The Navy Controlled release microstructures
US5651976A (en) * 1993-06-17 1997-07-29 The United States Of America As Represented By The Secretary Of The Navy Controlled release of active agents using inorganic tubules
US5705191A (en) * 1995-08-18 1998-01-06 The United States Of America As Represented By The Secretary Of The Navy Sustained delivery of active compounds from tubules, with rational control
US6936215B1 (en) * 1996-08-27 2005-08-30 The United States Of America As Represented By The Secretary Of The Navy Processing methodology for the rational control of bilayer numbers leading to high efficiency production of lipid microtubules
US5858924A (en) 1996-09-24 1999-01-12 Dow Agrosciences Llc N-( 1, 2, 4! triazoloazinyl) benzenesulfonamide and pyridinesulfonamide compounds and their use as herbicides
US6013206A (en) * 1998-05-18 2000-01-11 The United States Of America As Represented By The Secretary Of The Navy Process for the formation of high aspect ratio lipid microtubules
AU3724100A (en) * 1999-03-03 2000-09-21 United States Of America As Represented By The Secretary Of The Navy, The An efficient method for subsurface treatments, including squeeze treatments
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6518222B2 (en) 2000-11-03 2003-02-11 Dow Agrosciences Llc N-([1,2,4] triazoloazinyl) thiophenesulfonamide compounds and their use as herbicides
DE60131015T2 (de) 2000-12-15 2008-07-10 Vertex Pharmaceuticals Inc., Cambridge Bakterielle gyrase-hemmer und deren verwendung
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2003249477A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
US7125476B2 (en) * 2003-01-30 2006-10-24 The United States Of America As Represented By The Secretary Of The Navy Microwave-attenuating composite materials, methods for preparing the same, intermediates for preparing the same, devices containing the same, methods of preparing such a device, and methods of attenuating microwaves
US20050065171A1 (en) 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EA012119B1 (ru) 2004-08-12 2009-08-28 Пфайзер Инк. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
EP1799680A2 (fr) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Derives de triazolopyridine comme agents antibacteriens
US7400490B2 (en) * 2005-01-25 2008-07-15 Naturalnano Research, Inc. Ultracapacitors comprised of mineral microtubules
EP1855548A2 (fr) 2005-02-04 2007-11-21 Senomyx, Inc. Molecules comprenantdes fractions organiques liées telles que des agents de sapidite destinés à des compositions comestibles
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
EP1832629B1 (fr) * 2006-03-10 2016-03-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pigment pour inhiber la corrosion comprenant un nanoreservoir d'un inhibiteur de corrosion
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
EP2029605A1 (fr) * 2006-06-06 2009-03-04 Schering Corporation Imidazopyrazines utilisees en tant qu'inhibiteur de proteine kinase
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物
AU2007272009A1 (en) 2006-07-12 2008-01-17 Syngenta Limited Triazolopyridine derivatives as herbicides
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
WO2008045393A2 (fr) 2006-10-11 2008-04-17 Amgen Inc. Composés d'imidazo- et de triazolo-pyridine et leurs procédés d'utilisation
WO2008065198A1 (fr) 2006-12-01 2008-06-05 Galapagos N.V. Composés de triazolopyridine pour le traitement de maladies dégénératives et inflammatoires
US20080248201A1 (en) * 2007-04-06 2008-10-09 Naturalnano Research, Inc. Polymeric coatings including nanoparticle filler
WO2008124153A1 (fr) 2007-04-10 2008-10-16 H. Lundbeck A/S Analogues d'heteroaryl-amides utilises en tant qu'antagonistes de p2x7
JP2010523725A (ja) 2007-04-16 2010-07-15 レオ ファーマ アクティーゼルスカブ 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CA2693232A1 (fr) 2007-07-18 2009-01-22 Novartis Ag Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase
WO2009017954A1 (fr) 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
CA2695989A1 (fr) 2007-08-10 2009-02-19 Glaxosmithkline Llc Entites chimiques bicycliques azotees pour traiter les infections virales
WO2009027736A2 (fr) 2007-08-27 2009-03-05 Astrazeneca Ab Composés chimiques 000-1
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
CA2691448A1 (fr) 2007-08-31 2009-03-05 Dominique Swinnen Composes de triazolopyridine et leur utilisation comme inhibiteurs de ask
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009048474A1 (fr) 2007-10-12 2009-04-16 Pharmacopeia, Inc. Dérivés de purinone substitués en position 2, 7 et 9 pour l'immunosuppression
AU2008328882A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
WO2009136663A1 (fr) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Dérivés hétérocycliques fusionnés et leur utilisation
WO2009155565A1 (fr) 2008-06-20 2009-12-23 Genentech, Inc. Composés triazolopyridine inhibiteurs de jak kinase et procédés
CN102131389A (zh) * 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010007100A1 (fr) 2008-07-15 2010-01-21 Cellzome Ltd Amino triazoles substitués en position 7 en tant qu’inhibiteurs de pi3k
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010186A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010189A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010187A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
US20100041891A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
JP2010070503A (ja) 2008-09-19 2010-04-02 Daiichi Sankyo Co Ltd 抗真菌作用２−アミノトリアゾロピリジン誘導体
WO2010057877A1 (fr) 2008-11-18 2010-05-27 Cellzome Limited Triazolo[1,5-a]pyridines 7-pyridinyle- ou phényl-substituées comme inhibiteurs de pi3k
HRP20160488T1 (hr) 2008-12-19 2016-06-17 Leo Pharma A/S Triazolopiridini kao inhibitori fosfodiesteraze za liječenje kožnih bolesti
WO2010092015A1 (fr) 2009-02-10 2010-08-19 Cellzome Limited Dérivés d'urée-triazolo[1,5-a]pyridine en tant qu'inhibiteurs de pi3k
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
EP2523949B1 (fr) * 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Nouveaux dérivés de triazole en tant que modulateurs de la secrétase gamma

Also Published As

Publication number Publication date
US8501936B2 (en) 2013-08-06
CA2763900A1 (fr) 2010-12-09
TW201100421A (en) 2011-01-01
AU2010254806C1 (en) 2016-07-07
TWI500614B (zh) 2015-09-21
NZ597140A (en) 2014-01-31
AU2010254806B2 (en) 2016-02-04
US8633173B2 (en) 2014-01-21
KR20120044966A (ko) 2012-05-08
CL2011003082A1 (es) 2012-06-08
AU2010254806A1 (en) 2012-01-19
US20130296312A1 (en) 2013-11-07
CN102459258B (zh) 2015-11-25
JP5684245B2 (ja) 2015-03-11
CN102459258A (zh) 2012-05-16
US20100311693A1 (en) 2010-12-09
BRPI1009637A2 (pt) 2019-04-30
WO2010141796A3 (fr) 2012-02-16
EP2438066A2 (fr) 2012-04-11
JP2012528886A (ja) 2012-11-15
MX2011012961A (es) 2012-01-30
WO2010141796A2 (fr) 2010-12-09

Similar Documents

Publication Publication Date Title
IL216609A0 (en) Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
IL219564A0 (en) Imidazo [1,2-a] pyridine compounds, synthesis thereof, and methods of using same
ZA201006728B (en) Polysubstituted 2-aryl-6-phenyl-imidazo[1,2-a]pyridine derivatives,and preparation and therapeutic use thereof
PT2262803E (pt) Derivados polissubstituídos de 2-aril-6-fenil-imidazo[1,2- a]piridinas, sua preparação e sua aplicação em terapêutica
SMT201700581T1 (it) 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
IL208247A0 (en) Polysubstituted derivatives of 6-heteroaryl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof
IL216226A0 (en) Cyclopenta [c] pyrrole-2-carboxylate derivatives, preparation thereof, and therapeutic use thereof
IL208245A0 (en) Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof
IL218490A0 (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
IL215286A0 (en) 9h-pyrrolo[2,3-b:5,4-c]dipridine azacarboline derivatives, preparation thereof, and therapeutic use thereof
IL215980A (en) An intermediate substance of Artemnam, a preparation containing it and methods for its preparation
IL206671A0 (en) N-HETEROCYCLIC-IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
IL206667A0 (en) 2-HETEROAROYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
IL215733A0 (en) 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof
EP2578586A4 (fr) Dérivés d'hexahydropyrrolo[3,4-b]pyrrole, leurs procédés de préparation et leurs utilisations pharmaceutiques
IL215512A0 (en) Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same
ZA201100251B (en) Substituted 1-benzyl-cinnolin-4(1h)-one derivatives,preparation thereof,and therapeutic use thereof
ZA201004641B (en) Derivatives of n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides,preparation thereof and therapeutic application thereof
EP2350212A4 (fr) Polyamino-acétonitriles, leurs procédés de préparation et leur utilisation
ZA201004646B (en) Derivatives of n-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides,preparation thereof and therapeutic application thereof
IL215601A0 (en) Sulphurated derivatives of resorcinol, preparation of same and cosmetic uses thereof
HK1168351A (en) Preparation and uses of 1,2,4-triazolo [1,5a]pyridine derivatives
IL206665A0 (en) 2-BENZOYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
HK1166066A (en) Substituted 1-alkylcinnolin-4(1h)-one derivatives, preparation thereof and therapeutic application of same
IL246841A0 (en) Bicyclic derivatives [2,2,2] and methods of use